Acute Reperfusion Therapy and Stroke Care in Asia after Successful Endovascular Trials

Stroke

Volumn 46, Issue 6, 2015, Pages 1474-1481

  Toyoda, Kazunori ^a   Koga, Masatoshi ^a   Hayakawa, Mikito ^a   Yamagami, Hiroshi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

anticoagulants; Asia; cerebral hemorrhage; intracranial atherosclerosis; stroke; thrombectomy; thrombolysis, therapeutic

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE REPERFUSION THERAPY; ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; ENDOVASCULAR ANEURYSM REPAIR; HUMAN; LIFESTYLE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT CARE; PERCUTANEOUS THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); ENDOVASCULAR SURGERY; FAR EAST; FEEDING BEHAVIOR; HEALTH CARE DELIVERY; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL HEMORRHAGES; ORGANIZATION AND MANAGEMENT; REPERFUSION; STANDARDS; STROKE; THROMBECTOMY; TRENDS;

CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE; ENDOVASCULAR PROCEDURES; FAR EAST; FIBRINOLYTIC AGENTS; FOOD HABITS; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL HEMORRHAGES; LIFE STYLE; REPERFUSION; STROKE; THROMBECTOMY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84942514260     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.008781     Document Type: Review

References (69)

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al; Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1:e259-e281. doi: 10.1016/S2214-109X(13)70089-5.
2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371:624-634. doi: 10.1056/NEJMoa1304127.
3. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013;12:1106-1114. doi: 10.1016/S1474-4422(13)70195-9.
4. Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, et al. Genetic variant RNF213 c.14576G A in various phenotypes of intracranial major artery stenosis/occlusion. Stroke. 2013;44:2894-2897. doi:10.1161/STROKEAHA.113.002477.
5. Jung KH, Lee SH, Kim BJ, Yu KH, Hong KS, Lee BC, et al; Korean Stroke Registry Study Group. Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke). Circ Cardiovasc Qual Outcomes. 2012;5:327-334. doi: 10.1161/CIRCOUTCOMES.111.963736.
6. Bang OY. Intracranial atherosclerosis: current understanding and perspectives. J Stroke. 2014;16:27-35. doi: 10.5853/jos.2014.16.1.27.
7. Sato S, Toyoda K, Matsuoka H, Okatsu H, Kasuya J, Takada T, et al. Isolated anterior cerebral artery territory infarction: dissection as an etiological mechanism. Cerebrovasc Dis. 2010;29:170-177. doi:10.1159/000262314.
8. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7:1056-1066. doi: 10.1016/S1474-4422(08)70240-0.
9. Fukutake T. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis. 2011;20:85-93. doi: 10.1016/j. jstrokecerebrovasdis.2010.11.008.
10. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, et al; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013;3:e003733
11. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176. doi: 10.1016/S1474-4422(09)70340-0.
12. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309-315. doi: 10.1016/j. jacc.2007.01.098.
13. Wasay M, Khatri IA, Kaul S. Stroke in South Asian countries. Nat Rev Neurol. 2014;10:135-143. doi: 10.1038/nrneurol.2014.13.
14. Xu AD, Wang YJ, Wang DZ; Chinese Stroke Therapy Expert Panel for Intravenous Recombinant Tissue Plasminogen Activator. Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel. CNS Neurosci Ther. 2013;19:543-548. doi: 10.1111/cns.12126.
15. Suwanwela NC. Stroke epidemiology in Thailand. J Stroke. 2014;16:1-7. doi: 10.5853/jos.2014.16.1.1.
16. Pandian JD, Sudhan P. Stroke epidemiology and stroke care services in India. J Stroke. 2013;15:128-134. doi: 10.5853/jos.2013.15.3.128.
17. Robert AA, Zamzami MM. Stroke in Saudi Arabia: a review of the recent literature. Pan Afr Med J. 2014;17:14. doi: 10.11604/pamj.2014.17.14.3015.
18. Aiyagari V, Pandey DK, Testai FD, Grysiewicz RA, Tsiskaridze A, Sacks C, et al. A prototype worldwide survey of diagnostic and treatment modalities for stroke. J Stroke Cerebrovasc Dis. 2015;24:290-296. doi:10.1016/j.jstrokecerebrovasdis.2014.08.002.
19. Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, et al; Japan Stroke Society. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis. 2013;22:571-600. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.001.
20. Yamaguchi T, Kikuchi H, Hayakawa T; Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dosecomparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo, Japan: Springer-Verlag; 1995:223-229.
21. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815. doi:10.1161/01.STR.0000227191.01792.e3.
22. Ramaiah SS, Yan B. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review. Cerebrovasc Dis. 2013;36:161-166. doi:10.1159/000354162.
23. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. doi: 10.1016/S0140-6736(07)60149-4.
24. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009;40:3591-3595. doi: 10.1161/STROKEAHA.109.562991.
25. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010;41:1984-1989. doi: 10.1161/STROKEAHA.110.589606.
26. Rha JH, Shrivastava VP, Wang Y, Lee KE, Ahmed N, Bluhmki E, et al; SITS Investigators. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). Int J Stroke. 2014;9(suppl A100):93-101. doi:10.1111/j.1747-4949.2012.00895.x.
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
28. Mehta RH, Cox M, Smith EE, Xian Y, Bhatt DL, Fonarow GC, et al; Get With The Guidelines-Stroke Program. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45:2263-2269. doi:10.1161/STROKEAHA.114.005019.
29. Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, et al; EXTEND Investigators. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke. 2012;7:74-80. doi:10.1111/j.1747-4949.2011.00730.x.
30. Kang DW, Sohn SI, Hong KS, Yu KH, Hwang YH, Han MK, et al. Reperfusion therapy in unclear-onset stroke based on MRI evaluation (RESTORE): a prospective multicenter study. Stroke. 2012;43:3278-3283. doi: 10.1161/STROKEAHA.112.675926.
31. Aoki J, Kimura K, Shibazaki K, Sakamoto Y. Negative fluid-attenuated inversion recovery-based intravenous thrombolysis using recombinant tissue plasminogen activator in acute stroke patients with unknown onset time. Cerebrovasc Dis Extra. 2013;3:35-45. doi: 10.1159/000348552.
32. Koga M, Toyoda K, Kimura K, Yamamoto H, Sasaki M, Hamasaki T, et al; THAWS Investigators. THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0?6 mg/kg (THAWS) Trial. Int J Stroke. 2014;9:1117-1124. doi: 10.1111/ijs.12360.
33. Kim BJ, Park JM, Kang K, Lee SJ, Ko Y, Kim JG, et al. Case characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South Korea. J Stroke. 2015;17:38-53. doi: 10.5853/jos.2015.17.1.38.
34. Liu LP, Wong LK, Wang DZ, Miao ZR. Current status of endovascular procedures in management of ischemic stroke in China. CNS Neurosci Ther. 2014;20:483-484. doi: 10.1111/cns.12281.
35. Yoshimura S, Sakai N, Okada Y, Kitagawa K, Kimura K, Tanahashi N, et al; Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry Investigators. Efficacy of endovascular treatment for acute cerebral large-vessel occlusion: analysis of nationwide prospective registry. J Stroke Cerebrovasc Dis. 2014;23:1183-1190. doi:10.1016/j.jstrokecerebrovasdis.2013.10.014.
36. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
37. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018. doi: 10.1056/NEJMoa1414792.
38. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
39. Gascou G, Lobotesis K, Machi P, Maldonado I, Vendrell JF, Riquelme C, et al. Stent retrievers in acute ischemic stroke: complications and failures during the perioperative period. AJNR Am J Neuroradiol. 2014;35:734-740. doi: 10.3174/ajnr.A3746.
40. Matias-Guiu JA, Serna-Candel C, Matias-Guiu J. Stroke etiology determines effectiveness of retrievable stents. J Neurointerv Surg. 2014;6:e11. doi: 10.1136/neurintsurg-2012-010395.
41. Yamamoto S, Yamagami H, Todo K, Kuramoto Y, Ishikawa T, Imamura H, et al. Correlation of middle cerebral artery tortuosity with successful recanalization using the Merci retrieval system with or without adjunctive treatments. Neurol Med Chir (Tokyo). 2014;54:113-119.
42. Zhu L, Liebeskind DS, Jahan R, Starkman S, Salamon N, Duckwiler G, et al. Thrombus branching and vessel curvature are important determinants of middle cerebral artery trunk recanalization with Merci thrombectomy devices. Stroke. 2012;43:787-792. doi: 10.1161/STROKEAHA.110.612986.
43. Masuda EM, Caps MT, Singh N, Yorita K, Schneider PA, Sato DT, et al. Effect of ethnicity on access and device complications during endovascular aneurysm repair. J Vasc Surg. 2004;40:24-29. doi: 10.1016/j. jvs.2004.02.035.
44. Kim TK, Rhim JK, Lee CJ, Oh SH, Chung BS. The limitations of thrombectomy with Solitaire™ AB as first-line treatment in acute ischemic stroke: a single center experience. J Cerebrovasc Endovasc Neurosurg. 2012;14:203-209. doi: 10.7461/jcen.2012.14.3.203.
45. Bae YJ, Jung C, Kim JH, Choi BS, Kim E, Han MK, et al. Potential for the use of the Solitaire stent for recanalization of middle cerebral artery occlusion without a susceptibility vessel sign. AJNR Am J Neuroradiol. 2014;35:149-155. doi: 10.3174/ajnr.A3562.
46. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383:333-341. doi: 10.1016/S0140-6736(13)62038-3.
47. Jiang WJ, Yu W, Du B, Gao F, Cui LY. Outcome of patients with ?70% symptomatic intracranial stenosis after Wingspan stenting. Stroke. 2011;42:1971-1975. doi: 10.1161/STROKEAHA.110.595926.
48. Shin YS, Kim BM, Suh SH, Jeon P, Kim DJ, Kim DI, et al. Wingspan stenting for intracranial atherosclerotic stenosis: clinical outcomes and risk factors for in-stent restenosis. Neurosurgery. 2013;72:596-604, discussion 604. doi: 10.1227/NEU.0b013e3182846e09.
49. Joint Working Group from the Japan Stroke Society, Japan Neurosurgical Society, and Japanese Society for Neuroendovascular Therapy. Guidelines for the stenting for intracranial atherosclerosis. Jpn J Stroke 2014;36:151-162 (in Japanese).
50. Alurkar A, Karanam LS, Oak S, Nayak S, Sorte S. Role of balloon-expandable stents in intracranial atherosclerotic disease in a series of 182 patients. Stroke. 2013;44:2000-2003. doi: 10.1161/STROKEAHA.113.001446.
51. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al; VISSIT Trial Investigators. Effect of a balloonexpandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313:1240-1248. doi: 10.1001/jama.2015.1693.
52. Toyoda K, Fujii K, Kamouchi M, Nakane H, Arihiro S, Okada Y, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci. 2004;221:11-17. doi: 10.1016/j.jns.2004.03.002.
53. Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T, et al. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients-A preliminary study. J Neurol Sci. 2012;313:132-136. doi: 10.1016/j.jns.2011.09.006.
54. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19. doi: 10.1056/NEJMoa1215340.
55. Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation. 2013;128:1656-1666. doi: 10.1161/CIRCULATIONAHA.113.003187.
56. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593. doi: 10.1161/01.STR.0000170642.39876.f2.
57. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al; Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke. 2008;39:1740-1745. doi: 10.1161/STROKEAHA.107.504993.
58. Toyoda K. Pharmacotherapy for the secondary prevention of stroke. Drugs. 2009;69:633-647. doi: 10.2165/00003495-200969060-00001.
59. Toyoda K, Uchiyama S, Hoshino H, Kimura K, Origasa H, Naritomi H, et al; CSPS.com Study Investigators. Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke. 2015;10:253-258. doi:10.1111/ijs.12420.
60. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482-490. doi: 10.1016/j. jstrokecerebrovasdis.2009.07.010.
61. Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, et al; SAMURAI Study Investigators. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAINVAF Study [published online ahead of print January 12, 2015]. Int J Stroke. http://onlinelibrary.wiley.com/doi/10.1111/ijs.12452/abstract. Accessed January 12, 2015.
62. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al; RELY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891-1896. doi: 10.1161/STROKEAHA.113.000990.
63. Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, et al; Executive Steering Committee and the ROCKET AF Study Investigators. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke. 2014;45:1739-1747. doi: 10.1161/STROKEAHA.113.002968.
64. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, et al; ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168:303-309.
65. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293. doi: 10.1056/NEJMoa044503.
66. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-2365. doi: 10.1056/NEJMoa1214609.
67. Qureshi AI, Palesch YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011;15:559-576. doi: 10.1007/s12028-011-9538-3.
68. Asplund K, Eriksson M, Persson O. Country comparisons of human stroke research since 2001: a bibliometric study. Stroke. 2012;43:830-837. doi: 10.1161/STROKEAHA.111.637249.
69. Song D, Tanaka E, Lee K, Sato S, Koga M, Kim YD, et al. Factors associated with early hospital arrival for ischemic stroke: analysis of two hospital registries in Korea and Japan. J Stroke. In press.